J 2021

The Clinical Significance of DJ1 and L1CAM Serum Level Monitoring in Patients with Endometrial Cancer

BEDNAŘÍKOVÁ, Markéta, Petra VINKLEROVÁ, Jana GOTTWALDOVÁ, Petra OVESNÁ, Jitka HAUSNEROVÁ et. al.

Základní údaje

Originální název

The Clinical Significance of DJ1 and L1CAM Serum Level Monitoring in Patients with Endometrial Cancer

Autoři

BEDNAŘÍKOVÁ, Markéta (203 Česká republika, domácí), Petra VINKLEROVÁ (203 Česká republika, domácí), Jana GOTTWALDOVÁ (203 Česká republika, domácí), Petra OVESNÁ (203 Česká republika, domácí), Jitka HAUSNEROVÁ (203 Česká republika, domácí), Luboš MINÁŘ (203 Česká republika, domácí), Michal FELSINGER (203 Česká republika, domácí), Dalibor VALÍK (203 Česká republika, domácí), Zdeňka ČERMÁKOVÁ (203 Česká republika, domácí) a Vít WEINBERGER (203 Česká republika, garant, domácí)

Vydání

Journal of Clinical Medicine, Basel, MDPI, 2021, 2077-0383

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30218 General and internal medicine

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 4.964

Kód RIV

RIV/00216224:14110/21:00122136

Organizační jednotka

Lékařská fakulta

UT WoS

000666157800001

Klíčová slova anglicky

tumor markers; endometrial cancer; DJ1; L1CAM

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 18. 10. 2021 12:48, Mgr. Tereza Miškechová

Anotace

V originále

Circulating tumor markers are not routinely used in patients with endometrial cancer (EC). This pilot study evaluated the role of monitoring new biomarkers DJ1 and L1CAM, in correlation with CA125 and HE4, for the effects of anticancer treatment and preoperative management in EC patients. Serial serum levels of DJ1, L1CAM, CA125 and HE4 were collected in 65 enrolled patients. Serum DJ1, L1CAM, CA125 and HE4 levels were significantly higher at the time of diagnosis compared to those measured during follow-up (FU). In patients with recurrent disease, serum DJ1, CA125 and HE4 levels were significantly higher at the time of recurrence compared to levels in disease-free patients. Serum L1CAM levels were also higher in patients with recurrence but without reaching statistical significance. While DJ1 levels were not affected by any of the observed patient-related characteristics, L1CAM levels were significantly higher in patients with age >= 60 years who were overweight. At the time of EC diagnosis, DJ1 and L1CAM serum levels did not correlate with stage, histological type or risk of recurrence. This is a preliminary description of the potential of serial DJ1 and L1CAM serum level measurement for monitoring the effects of treatment in EC patients.